ClinicalTrials.gg
Active, not recruitingNCT06524336Updated Jul 29, 2024

Host Immune Dynamics Following Seasonal Malaria Chemoprevention in African Children

An observational study in Malaria,Falciparum, sponsored by Malaria Consortium. Active, not recruiting at 1 site in Uganda. Open to participants aged 3 Months to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-29.

Sponsored by Malaria Consortium · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
300
Ages
3 Months to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Malaria, Falciparum with a site in Uganda — 8 open to participants now, 11 under way, none of them phase 3. Malaria, Falciparum · Uganda.

Started
2024
with 4 others
Observational
7 of 27
2 open now
Primary completion
2024-10
later than 0 of 10 live
Registered
17th of 27
by date

Among the 27 studies in Malaria, Falciparum with a site in Uganda, this one is one of 5 that started in 2024, is one of 7 observational ones, reaches primary completion later than 0 of the 10 other live ones, and was the 17th registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

8 of the 27 studies in Malaria, Falciparum with a site in Uganda are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Uganda have not opened yet or have stopped. Only those recruiting at a site in Uganda →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 3 Months to 15 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Malaria, Falciparum with a site in Uganda, or all of them as a file.
02

Study summary

The study aims to identify immune features linked to protection against malaria, examining variations by age and sex, and measuring changes in immune responses over time following seasonal malaria chemoprevention (SMC). The primary objectives are:

  1. Thorough examination of antibody immune responses in individuals before and after one or more SMC rounds.
  2. Thorough examination of both innate and adaptive cellular immune responses in people residing in areas with regular SMC use.

Participants will include children aged 3 to 59 months who have received at least two or three SMC rounds, as well as children aged 5 to 15 years with no prior SMC exposure.

Upon identifying participants, study details will be provided, and written informed consent obtained. Demographic and clinical information will be collected using standard case record forms, including previous SMC uptake and routine malaria control interventions. Information on SMC use will be obtained from SMC cards/existing medical records, detailing the number of cycles received, adherence, and general health condition, including previous diseases and EPI vaccine uptake.

Data Collection:

  • Face-to-face interviews by trained research assistants.
  • Clinical assessments, including temperature, weight, and mid-upper arm circumference (MUAC).
  • Sickle cell status testing at enrolment via samples analyzed at the Molecular Research Laboratory (MOLAB).
  • Hemoglobin measurement using a HemoCue analyzer.

Malaria Diagnosis:

  • Blood samples collected for malaria diagnosis using rapid diagnostic tests (RDTs) and microscopy.
  • RDTs, such as Paracheck Pf, will be performed according to manufacturer instructions, with results available within 15 minutes.
  • Participants testing positive for malaria will receive a full course of antimalarial treatment and counselling to visit the nearest health facility if symptoms worsen.

Thick Blood Smears:

  • New glass slides labelled with participant ID will be used for thick blood smears.
  • Blood smears will be dried and stored in a cool, dust-free environment before transportation to central laboratories.
  • Slides will be stained with 2% Giemsa for 30 minutes and evaluated for parasitemia and gametocytes, with densities calculated accordingly.

The study will help understand the immune responses to malaria and the efficacy of SMC in different age groups.

Read the detailed description

This will be a prospective cohort study with participant enrolment done in two districts in the Karamoja sub region.

The study population will consist of children aged 3 to 59 months - the target age group for SMC. A representative sample of children in the 5-15 years age group to characterize immune dynamics and responses in this age group as a comparator age group will be enrolled as well.

Inclusion criteria

  • Children aged 3 to 59 months and 5-15 years in the selected districts
  • Provision of Informed consent by parents/caregivers

Exclusion criteria

  • Children known to be immunosuppressed due to malnutrition, HIV or other chronic diseases

When participants are identified, further details about the study will be provided and written informed consent will be obtained. Demographic and clinical information will then be collected using standard case record forms. Information will be collected on previous uptake of SMC and routine use of malaria control interventions. Information on previous SMC use will be obtained through a review of SMC cards/existing medical records. This information will include number of cycles/rounds received, adherence to SMC medication at each of these cycles and number of SMC rounds. Information will also be collected on general health condition of the child including previous diseases and EPI vaccine uptake (verified by immunization card). All participants will be interviewed face-to-face by trained research assistants and will be asked a series of questions. This will be followed by clinical assessment that include measurement of temperature, weight and mid-upper arm circumference (MUAC).

At enrolment, sickle cell status will be ascertained via testing of samples at the Molecular Research laboratory (MOLAB). Venipuncture blood samples will be collected at enrolment for sickle cell testing and hemoglobin measurement. Hemoglobin analysis will be carried out using a drop of blood (approximately 0.2mls) from the EDTA sample collected. The test will be conducted using a battery-operated portable HemoCue analyzer (HemoCue, Anglom, Sweden) which provides a result within one minute.

All enrolled participants will have blood samples collected for malaria diagnosis using rapid diagnostic tests (RDTs) and microscopy. Samples will also be collected for molecular analysis as needed.

Paracheck Pf, from Orchid Biomedical System, India or any other type of RDTs recommended by the Ministry of Health will be used. RDTs will be performed according to the directions provided for the specific tests, using the blood transfer device and reagent provided by the manufacturer. Tests will be performed by study personnel, and results will be available within 15 minutes. The results of the RDT will be provided to the participant or their parent/guardian verbally, and will be recorded on the appropriate case record form. Participants who test positive for malaria will be provided a full course of antimalarial treatment and will also be counselled to go to the nearest health facility immediately if their illness worsens.

New glass slides, frosted at one end, will be used to make the thick blood smears. Before making the smears, the lab technician will appropriately label the glass slides at the frosted end with the participant ID. Thick blood smears will be made by placing a drop of blood in the middle of the slide. An applicator stick will be used to spread the blood into a spot of approximately 1 cm in diameter. The blood smear will be dried on a slide tray in an ideally dust-free environment. For study sites away from the coordinating center, slides will be kept at the study health facilities protected from excessive heat and light for no longer than 1 week to avoid auto-fixation. The slides will be kept in a slide box and stored in the coolest place possible. The blood slides will then be transported to designated central laboratories. Thick blood smears will be stained with 2% Giemsa for 30 minutes and will be evaluated for the presence of parasitaemia (asexual forms only) and gametocytes. Parasite and gametocyte densities will be calculated from thick blood smears by counting the number of asexual parasites and gametocytes, respectively, per 200 leukocytes (or per 500, if the count is less than 10 parasites or gametocytes per 200 leukocytes), assuming a leukocyte count of 8,000/µl. A thick blood smear will be considered negative when the examination of 100 high power fields does not reveal asexual parasites or gametocytes. For quality control, all slides will be read by a second microscopist and a third reviewer will settle any discrepant readings.

Each time a thick blood smear is obtained blood will also be collected onto filter paper. Samples will be collected by venipuncture or by finger-prick sampling. Filter paper (Whatman no 1, Whatman 3MM; Whatman, Maidstone, UK) will be pre-cut into individual squares and stapled to a thick card which will serve as its cover. Blood spots will be collected onto the filter paper in volumes of approximately 25 µl per blood spot (4 blood spots per sample). Filter paper samples will be labelled with bar codes on the covering cardboard and will be allowed to dry at ambient temperature and relative humidity before closing the card over the filter paper (like closing a matchbook). Filter paper samples will be transported from the field in zip lock bags and placed into a stock card filter paper box for final storage at ambient temperature or at -20⁰C with a desiccant. Filter paper samples will be stored at our partner laboratory at IDRC in Kampala for future studies. Future molecular studies will be performed only for research purposes and will have no impact on the clinical management of study participants.

Molecular studies will include the extraction of DNA and/or RNA from filter paper, followed by characterization of parasite and host nucleic acid sequences using standard molecular procedures including PCR, DNA hybridization, restriction enzyme digestion, and/or nucleic acid sequencing. These will be performed at the CPHL laboratories where genomics capacity is already established.

Venipuncture blood samples will be collected aseptically by trained laboratory technologists. Approximately 6 mls of blood will be collected from children below 5 years and up to 10ml from children above 5 years in Heparin or EDTA tubes. This whole blood will be stored in either specific fixatives, including Paxgene reagent, used to assess cellular gene expression, and/or separated into plasma and peripheral blood mononuclear cells (PBMC) using a Ficoll gradient, following standard protocols. PBMC and plasma will be isolated from blood samples collected from enrolled participants at the central processing Laboratory at Moroto Hospital.

Whole blood collected in paxgene reagent will be stored at -80°C for whole blood transcriptomic studies. Plasma will be stored at -80°C for plasma-based immunologic studies, which will include measurement of levels of cytokines and other circulating inflammatory proteins (e.g., pro-inflammatory and anti-inflammatory cytokines), antibodies (e.g., malaria-specific antibodies), and/or other features related to the host immune response. PBMCs will be isolated by density gradient centrifugation (Ficoll-Histopaque; GE Life Sciences), counted, and cryopreserved in liquid nitrogen. PBMCs will be used to evaluate the innate and adaptive immune response e.g. malaria-specific T cell responses by flow cytometry, RNA sequencing, cytometry by time of flight (CyTOF), and/or other assays to assess the host immune response. Several of these assays utilizing PBMCs will be performed in our partner laboratories in Uganda. For all specimen types, two samples aliquots will be prepared, one for analysis in Uganda, and the other to be shipped to Stanford for additional immunology assays that are not available in Uganda.

De-identified plasma obtained from malaria-naïve, donors will be used as controls. For antibody functional assays (antibody-dependent cellular cytotoxicity or phagocytosis), large quantities of PBMCs for stimulation assays in immunology analyses will be obtained from blood bank donors at designated regional blood banks.

A comprehensive and longitudinal profiling of a broad array of host immune responses will be conducted to evaluate the impact of SMC on host immunity to malaria. To broadly profile the antibody response, a multiplex assessment of malaria-specific antibody responses will be performed using MagPix/Luminex, utilizing plasma collected from study participants in Uganda. Plasma antibody levels, subclass, and avidity will be measured, along with several additional Fc-dependent functional features of the antibody response, including complement fixation and antibody-dependent cellular cytotoxicity. The Luminex multiplex bead array assay to determine IgG levels, subclass, Fc receptor binding, and avidity against >18 pre-erythrocytic and blood-stage malarial antigens, including CSP, AMA-1, MSP1, MSP2, Rh5 and others will be performed at our collaborating partner laboratories in Kampala. In collaboration with partners at Stanford University (PI Jagannathan), the Luminex assay will be further optimized to study additional functional features of the antibody response. This includes complement fixation, antibody-dependent cellular cytotoxicity, and phagocytosis, which will be assessed as needed.

To comprehensively and longitudinally profile the innate and adaptive cellular immune responses in participants living in this area with sustained SMC, cellular phenotypes, function, and gene expression will be broadly measured from PBMCs collected from the same individuals over time. To study systems-level changes in cellular immune profiles in individuals, whole blood RNA sequencing will be performed using blood collected from Paxgene tubes, and plasma proteomics will be conducted using a nucleic-acid linked immune-sandwich assay. As these assays are not available in Uganda, they will be performed in the laboratory of collaborators at Stanford.

Multiparameter flow cytometry will be used to study innate and adaptive cellular phenotypes at the single-cell level. To study the functional response of individual immune cells, optimized stimulation assays with malaria antigens will be used. Phenotyping and functional assays will be conducted at a designated laboratory in Tororo or Kampala. In collaboration with partners at Stanford University (PI Jagannathan), additional assessments of the functional state of innate and adaptive immune cells will be performed, including epigenetics by time of flight (EpiTOF), single-cell RNA sequencing, and single-cell T and B cell receptor sequencing.

Plasma samples will also be stored for future In-depth analysis of the differential abundances of serum/plasma proteins which may help in identification of surrogate markers that and can provide valuable information regarding disease pathogenesis and host immune responses. This is important as there is currently a dearth of proteomic analysis in these settings.

All statistical analyses will be performed using STATA version 16 (College Station) or R version 4.2.0. Comparisons of cellular percentages between groups will be performed using the Wilcoxon rank sum and/or t test, and the Wilcoxon signed-rank and/or paired t test will be used to compare paired data. Associations between continuous variables will be assessed using Spearman's rank correlation. Two-sided p-values will be calculated for all test statistics and P \< 0.05 will be considered significant.

03

Conditions studied

  • Malaria,Falciparum

Keywords

  • malaria
  • blood stage immunity
  • anti-disease immunity
  • SMC
04

Who can participate

Ages eligible
3 Months to 15 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of children aged 3 to 59 months - the target age group for SMC. We will also enroll a representative sample of children in the 5-15 years age group to characterize immune dynamics and responses in this age group as a comparator age group.

These children will be further categorized into different groups according to their previous exposure to SMC to include the following;

  • Group 1: Children with no prior intake of SMC (Katakwi district) - we will enroll a total of 40 children in this group in the two age categories (3 to 59 months and 5-15 years)
  • Group 2: Children who have received at least two rounds of SMC (Napak district) - we will enroll 130 children aged 3 to 59 months in this group
  • Group 3: Children who have received at least three rounds of SMC (Moroto district) - we will enroll 130 children aged 3 to 59 months in this group

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 3 to 59 months and 5-15 years in the selected districts
  • Provision of by parents/caregivers

Exclusion criteria

Exclusion Criteria:

  • Children known to be due to malnutrition, or other chronic diseases
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
300 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Antibody immune response

    Number of study participants with protective antimalarial antibodies

    Time frame: one year

  2. Innate and adaptive immune responses

    Number of study participants with cellular phenotypes and functions that are protective from malaria

    Time frame: one year

Secondary outcomes

  1. surrogate markers that predict risk of malaria

    Number of individuals with surrogate markers that predict risk of malaria

    Time frame: one year

07

Study locations

1 site
  • Moroto Hospital
    Moroto, Karamoja, Uganda
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Oct 2024, 4 months after the start.

Of 20 observational studies under Malaria, Falciparum, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2024
First posted
Jul 29, 2024
StartActual
Jun 12, 2024
Primary completionEst.
Oct 28, 2024
CompletionEst.
Oct 28, 2024
Last update
Jul 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06524336
Lead sponsor
Malaria Consortium
Collaborators
Stanford University
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Jun 12, 2024
Primary completion
Oct 28, 2024 (estimated)
Completion
Oct 28, 2024 (estimated)
Last update
Jul 29, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion